US7053070B2
(en)
*
|
2000-01-25 |
2006-05-30 |
Warner-Lambert Company |
Pyrido[2,3-d]pyrimidine-2,7-diamine kinase inhibitors
|
JP2005507392A
(ja)
*
|
2000-08-04 |
2005-03-17 |
ワーナー−ランバート・カンパニー、リミテッド、ライアビリティ、カンパニー |
2−(4−ピリジル)アミノ−6−ジアルキルオキシフェニルピリド〔2,3−d〕ピリミジン−7−オン類の製造方法
|
JP2004505974A
(ja)
*
|
2000-08-04 |
2004-02-26 |
ワーナー−ランバート・カンパニー、リミテッド、ライアビリティ、カンパニー |
2−(4−ピリジル)アミノ−6−ジアルキルオキシフェニルピリド〔2,3−d〕ピリミジン−7−オン類の製造方法
|
WO2002064594A2
(en)
*
|
2001-02-12 |
2002-08-22 |
F. Hoffmann-La Roche Ag |
6-substituted pyrido-pyrimidines
|
JP4166991B2
(ja)
*
|
2001-02-26 |
2008-10-15 |
田辺三菱製薬株式会社 |
ピリドピリミジンまたはナフチリジン誘導体
|
WO2003000270A1
(en)
*
|
2001-06-21 |
2003-01-03 |
Ariad Pharmaceuticals, Inc. |
Novel pyridopyrimidones and uses thereof
|
US20050154046A1
(en)
*
|
2004-01-12 |
2005-07-14 |
Longgui Wang |
Methods of treating an inflammatory-related disease
|
DE60303009T2
(de)
|
2002-01-22 |
2006-07-13 |
Warner-Lambert Co. Llc |
2-(pyridin-2-ylamino)-pyrido[2,3-d]pyrimidin-7-one
|
ES2293064T3
(es)
*
|
2002-08-06 |
2008-03-16 |
F. Hoffmann-La Roche Ag |
6-alcoxi-pirido-pirimidinas como inhibidores de la p-38 map quinasa.
|
US7112676B2
(en)
|
2002-11-04 |
2006-09-26 |
Hoffmann-La Roche Inc. |
Pyrimido compounds having antiproliferative activity
|
US7759336B2
(en)
|
2002-12-10 |
2010-07-20 |
Ono Pharmaceutical Co., Ltd. |
Nitrogen-containing heterocyclic compounds and medicinal use thereof
|
WO2004089955A1
(en)
|
2003-04-10 |
2004-10-21 |
F.Hoffmann-La Roche Ag |
Pyrimido compounds
|
ATE412650T1
(de)
*
|
2003-07-11 |
2008-11-15 |
Warner Lambert Co |
Isethionat salz eines selektiven cdk4 inhibitors
|
CA2532965C
(en)
|
2003-07-22 |
2013-05-14 |
Astex Therapeutics Limited |
3, 4-disubstituted 1h-pyrazole compounds and their use as cyclin dependent kinases (cdk) and glycogen synthase kinase-3 (gsk-3) modulators
|
AU2004261250B2
(en)
*
|
2003-07-29 |
2009-02-26 |
Xenon Pharmaceuticals Inc. |
Pyridyl derivatives and their use as therapeutic agents
|
CA2544247A1
(en)
*
|
2003-11-13 |
2005-05-26 |
David Michael Goldstein |
Hydroxyalkyl substituted pyrido-7-pyrimidin-7-ones
|
WO2005058341A2
(en)
*
|
2003-12-11 |
2005-06-30 |
Theravance, Inc. |
Compositions for use in the treatment of mutant receptor tyrosine kinase driven cellular proliferative diseases
|
JP4989233B2
(ja)
*
|
2004-02-14 |
2012-08-01 |
アイアールエム・リミテッド・ライアビリティ・カンパニー |
タンパク質キナーゼ阻害剤としての化合物および組成物
|
CA2555724A1
(en)
*
|
2004-02-18 |
2005-09-09 |
Warner-Lambert Company Llc |
2-(pyridin-3-ylamino)-pyrido[2,3-d]pyrimidin-7-ones
|
CA2561516A1
(en)
*
|
2004-03-30 |
2005-10-13 |
Pfizer Products Inc. |
Combinations of signal transduction inhibitors
|
RS50569B
(sr)
*
|
2004-06-11 |
2010-05-07 |
Japan Tobacco Inc. |
Derivati 5-amino-2,4,7-triokso-3,4,7,8-tetrahidro-2h-pirido (2,3-d)pirimidina i slična jedinjenja za lečenje raka
|
US7378423B2
(en)
|
2004-06-11 |
2008-05-27 |
Japan Tobacco Inc. |
Pyrimidine compound and medical use thereof
|
CA2586761A1
(en)
|
2004-11-10 |
2006-05-18 |
Genzyme Corporation |
Methods of treating diabetes mellitus
|
US20060142312A1
(en)
*
|
2004-12-23 |
2006-06-29 |
Pfizer Inc |
C6-aryl and heteroaryl substituted pyrido[2,3-D] pyrimidin-7-ones
|
ES2552338T3
(es)
*
|
2005-01-21 |
2015-11-27 |
Astex Therapeutics Limited |
Compuestos farmacéuticos
|
EP1845975A1
(en)
*
|
2005-01-21 |
2007-10-24 |
Astex Therapeutics Limited |
Combinations of pyrazole kinase inhibitors and further antitumor agents
|
AU2006207321B2
(en)
*
|
2005-01-21 |
2012-09-06 |
Astex Therapeutics Limited |
Pharmaceutical compounds
|
AR054425A1
(es)
|
2005-01-21 |
2007-06-27 |
Astex Therapeutics Ltd |
Sales de adicion de piperidin 4-il- amida de acido 4-(2,6-dicloro-benzoilamino) 1h-pirazol-3-carboxilico.
|
US8404718B2
(en)
|
2005-01-21 |
2013-03-26 |
Astex Therapeutics Limited |
Combinations of pyrazole kinase inhibitors
|
WO2006090853A1
(ja)
|
2005-02-25 |
2006-08-31 |
Ono Pharmaceutical Co., Ltd. |
含窒素複素環化合物およびその医薬用途
|
TW200724142A
(en)
*
|
2005-03-25 |
2007-07-01 |
Glaxo Group Ltd |
Novel compounds
|
PE20100737A1
(es)
*
|
2005-03-25 |
2010-11-27 |
Glaxo Group Ltd |
Nuevos compuestos
|
DK2559690T3
(en)
|
2005-05-10 |
2016-04-25 |
Incyte Holdings Corp |
Modulators of indoleamine 2,3-dioxygenase and methods of use thereof
|
KR100734837B1
(ko)
*
|
2005-09-16 |
2007-07-03 |
한국전자통신연구원 |
다중 생체 인식 시스템 및 그 방법
|
EP1931667A1
(en)
*
|
2005-09-28 |
2008-06-18 |
Ranbaxy Laboratories Limited |
Pyrido-pyridimidine derivatives useful as antiinflammatory agents
|
WO2007044813A1
(en)
*
|
2005-10-07 |
2007-04-19 |
Exelixis, Inc. |
PYRIDOPYRIMIDINONE INHIBITORS OF PI3Kα
|
AU2006302148B2
(en)
*
|
2005-10-07 |
2012-12-06 |
Exelixis, Inc. |
Pyridopyrimidinone inhibitors of PI3Kalpha
|
US20090142337A1
(en)
*
|
2006-05-08 |
2009-06-04 |
Astex Therapeutics Limited |
Pharmaceutical Combinations of Diazole Derivatives for Cancer Treatment
|
PT2032134E
(pt)
|
2006-05-09 |
2015-10-07 |
Genzyme Corp |
Métodos de tratamento da doença do fígado gorduroso
|
KR20090052385A
(ko)
*
|
2006-09-08 |
2009-05-25 |
화이자 프로덕츠 인크. |
2-(피리딘-2-일아미노)-피리도[2,3-d]피리미딘-7-온의합성
|
CN101573358B
(zh)
|
2006-09-15 |
2012-05-30 |
辉瑞产品公司 |
吡啶并(2,3-d)嘧啶酮化合物及其作为pi3抑制剂的用途
|
EP1914234A1
(en)
|
2006-10-16 |
2008-04-23 |
GPC Biotech Inc. |
Pyrido[2,3-d]pyrimidines and their use as kinase inhibitors
|
EP2084159A1
(en)
*
|
2006-10-16 |
2009-08-05 |
GPC Biotech Inc. |
Pyrido ý2, 3-d¨pyrimidines and their use as kinase inhibitors
|
WO2008150260A1
(en)
*
|
2007-06-06 |
2008-12-11 |
Gpc Biotech, Inc. |
8-oxy-2-aminopyrido (2, 3-d) pyrimidin-7-one derivatives as kinase inhibitors and anticancer agents
|
EP2094698A1
(en)
*
|
2006-11-09 |
2009-09-02 |
F. Hoffmann-Roche AG |
Substituted 6-phenyl-pyrido [2,3-d]pyrimidin-7-one derivatives as kinase inhibitors and methods for using the same
|
WO2008063888A2
(en)
|
2006-11-22 |
2008-05-29 |
Plexxikon, Inc. |
Compounds modulating c-fms and/or c-kit activity and uses therefor
|
MX337396B
(es)
|
2007-10-05 |
2016-03-02 |
Genzyme Corp |
Metodo para el tratamiento de enfermedades del riñon poliquisticas con derivados de ceramica.
|
WO2009085185A1
(en)
|
2007-12-19 |
2009-07-09 |
Amgen Inc. |
Fused pyridine, pyrimidine and triazine compounds as cell cycle inhibitors
|
MX2010010975A
(es)
|
2008-04-07 |
2010-11-01 |
Amgen Inc |
Amino piridinas/pirimidinas gem-disustituidas y espirociclicas como inhibidores de ciclo celular.
|
EP2112150B1
(en)
|
2008-04-22 |
2013-10-16 |
Forma Therapeutics, Inc. |
Improved raf inhibitors
|
PL2315756T3
(pl)
|
2008-07-08 |
2015-02-27 |
Incyte Holdings Corp |
1,2,5-oksadiazole jako inhibitory 2,3-dioksygenazy indoloaminy
|
EP2320886B1
(en)
|
2008-07-28 |
2017-06-28 |
Genzyme Corporation |
Glucosylceramide synthase inhibition for the treatment of collapsing glomerulopathy and other glomerular disease
|
PT2331547E
(pt)
*
|
2008-08-22 |
2014-10-29 |
Novartis Ag |
Compostos de pirrolopirimidina como inibidores de cdk
|
WO2010039997A2
(en)
*
|
2008-10-01 |
2010-04-08 |
The University Of North Carolina At Chapel Hill |
Hematopoietic protection against chemotherapeutic compounds using selective cyclin-dependent kinase 4/6 inhibitors
|
CN102231983A
(zh)
*
|
2008-10-01 |
2011-11-02 |
北卡罗来纳大学查珀尔希尔分校 |
使用选择性细胞周期蛋白依赖性激酶4/6抑制剂对抗电离辐射的造血防护
|
CN107935983A
(zh)
|
2008-10-03 |
2018-04-20 |
简詹姆公司 |
2‑酰胺基丙醇型葡糖神经酰胺合酶抑制剂
|
PA8852901A1
(es)
|
2008-12-22 |
2010-07-27 |
Lilly Co Eli |
Inhibidores de proteina cinasa
|
ES2552386T3
(es)
|
2009-04-03 |
2015-11-27 |
F. Hoffmann-La Roche Ag |
Composiciones de {3-[5-(4-cloro-fenil)-1H-pirrol[2,3-b]piridin-3-carbonil]-2,4-difluoro-fenil}-amida del ácido propano-1-sulfónico y usos de las mismas
|
JP2012526850A
(ja)
|
2009-05-13 |
2012-11-01 |
ザ ユニバーシティ オブ ノース カロライナ アット チャペル ヒル |
サイクリン依存性キナーゼ阻害剤及びその用法
|
EP2474540A4
(en)
*
|
2009-08-31 |
2013-03-13 |
Nippon Chemiphar Co |
GPR119 AGONIST
|
KR20120104200A
(ko)
*
|
2009-10-09 |
2012-09-20 |
아프락시스 인코포레이티드 |
Cns 장애의 치료를 위한 8에틸6(아릴)피리도[2,3d]피리미딘7(8h)온
|
ES2633317T3
(es)
|
2009-11-06 |
2017-09-20 |
Plexxikon, Inc. |
Compuestos y métodos para la modulación de quinasas, e indicaciones para ello
|
WO2011075616A1
(en)
*
|
2009-12-18 |
2011-06-23 |
Temple University - Of The Commonwealth System Of Higher Education |
Substituted pyrido[2,3-d]pyrimidin-7(8h)-ones and therapeutic uses thereof
|
EP2519526B1
(en)
|
2009-12-31 |
2014-03-26 |
Centro Nacional de Investigaciones Oncológicas (CNIO) |
Tricyclic compounds for use as kinase inhibitors
|
CN102869358B
(zh)
|
2010-04-13 |
2016-03-23 |
诺华股份有限公司 |
用于治疗癌症的包含细胞周期蛋白依赖性激酶4或细胞周期蛋白依赖性激酶6(CDK4/6)抑制剂和mTOR抑制剂的组合
|
TWI510487B
(zh)
|
2010-04-21 |
2015-12-01 |
Plexxikon Inc |
用於激酶調節的化合物和方法及其適應症
|
US8680099B2
(en)
*
|
2010-06-10 |
2014-03-25 |
Afraxis Holdings, Inc. |
6-(ethynyl)pyrido[2,3-D]pyrimidin-7(8H)-ones for the treatment of CNS disorders
|
WO2011159726A2
(en)
|
2010-06-14 |
2011-12-22 |
The Scripps Research Institute |
Reprogramming of cells to a new fate
|
NZ606281A
(en)
|
2010-08-05 |
2014-09-26 |
Univ Temple |
2-substituted-8-alkyl-7-oxo-7,8-dihydropyrido[2,3-d]pyrimidine-6-carbonitriles and uses thereof
|
RS55135B1
(sr)
|
2010-10-25 |
2016-12-30 |
G1 Therapeutics Inc |
Cdk inhibitori
|
US8691830B2
(en)
|
2010-10-25 |
2014-04-08 |
G1 Therapeutics, Inc. |
CDK inhibitors
|
AU2011329763A1
(en)
|
2010-11-17 |
2013-05-09 |
Brigham And Women's Hospital |
Protection of renal tissues from ischemia through inhibition of the proliferative kinases CDK4 and CDK6
|
US8754114B2
(en)
|
2010-12-22 |
2014-06-17 |
Incyte Corporation |
Substituted imidazopyridazines and benzimidazoles as inhibitors of FGFR3
|
WO2012098387A1
(en)
|
2011-01-18 |
2012-07-26 |
Centro Nacional De Investigaciones Oncológicas (Cnio) |
6, 7-ring-fused triazolo [4, 3 - b] pyridazine derivatives as pim inhibitors
|
TR201816421T4
(tr)
|
2011-02-07 |
2018-11-21 |
Plexxikon Inc |
Kinaz modülasyonu için bileşikler ve metotlar ve bunların endikasyonları.
|
EP2937349B1
(en)
|
2011-03-23 |
2016-12-28 |
Amgen Inc. |
Fused tricyclic dual inhibitors of cdk 4/6 and flt3
|
AU2012262489A1
(en)
|
2011-05-27 |
2013-04-04 |
Icahn School Of Medicine At Mount Sinai |
Substituted 2-benzylidene-2H-benzo[b][1,4]thiazin-3(4H)-ones, derivatives thereof, and therapeutic uses thereof
|
SG11201405007QA
(en)
*
|
2012-03-14 |
2014-10-30 |
Lupin Ltd |
Heterocyclyl compounds
|
EP2831080B1
(en)
|
2012-03-29 |
2017-03-15 |
Francis Xavier Tavares |
Lactam kinase inhibitors
|
US9150570B2
(en)
|
2012-05-31 |
2015-10-06 |
Plexxikon Inc. |
Synthesis of heterocyclic compounds
|
ES2618003T3
(es)
|
2012-06-13 |
2017-06-20 |
Incyte Holdings Corporation |
Compuestos tricíclicos sustituidos como inhibidores de FGFR
|
MX369472B
(es)
|
2012-07-11 |
2019-11-08 |
Blueprint Medicines Corp |
Inhibidores del receptor del factor de crecimiento de fibroblastos.
|
EP4119676A1
(en)
|
2012-08-03 |
2023-01-18 |
Foundation Medicine, Inc. |
Human papilloma virus as predictor of cancer prognosis
|
US9388185B2
(en)
|
2012-08-10 |
2016-07-12 |
Incyte Holdings Corporation |
Substituted pyrrolo[2,3-b]pyrazines as FGFR inhibitors
|
EA031716B1
(ru)
|
2012-08-17 |
2019-02-28 |
Консерт Фармасьютикалс, Инк. |
Дейтерированный барицитиниб
|
US9266892B2
(en)
|
2012-12-19 |
2016-02-23 |
Incyte Holdings Corporation |
Fused pyrazoles as FGFR inhibitors
|
US20150353542A1
(en)
|
2013-01-14 |
2015-12-10 |
Amgen Inc. |
Methods of using cell-cycle inhibitors to modulate one or more properties of a cell culture
|
WO2014128588A1
(en)
|
2013-02-21 |
2014-08-28 |
Pfizer Inc. |
Solid forms of a selective cdk4/6 inhibitor
|
CN105407723A
(zh)
|
2013-03-15 |
2016-03-16 |
G1治疗公司 |
高效的抗赘生剂和抗增生剂
|
US9487530B2
(en)
|
2013-03-15 |
2016-11-08 |
G1 Therapeutics, Inc. |
Transient protection of normal cells during chemotherapy
|
US20160024084A1
(en)
|
2013-03-15 |
2016-01-28 |
Concert Pharmaceuticals, Inc. |
Deuterated palbociclib
|
US9533984B2
(en)
|
2013-04-19 |
2017-01-03 |
Incyte Holdings Corporation |
Bicyclic heterocycles as FGFR inhibitors
|
WO2014183520A1
(zh)
*
|
2013-05-17 |
2014-11-20 |
上海恒瑞医药有限公司 |
吡啶并嘧啶类衍生物、其制备方法及其在医药上的应用
|
WO2014203129A1
(en)
|
2013-06-19 |
2014-12-24 |
Olema Pharmaceuticals, Inc. |
Combinations of benzopyran compounds, compositions and uses thereof
|
DK3395814T3
(da)
|
2013-10-25 |
2022-07-04 |
Blueprint Medicines Corp |
Hæmmere af fibroblastvækstfaktorreceptoren
|
US11013743B2
(en)
*
|
2013-12-20 |
2021-05-25 |
Biomed Valley Discoveries, Inc. |
Cancer treatments using combinations of CDK and ERK inhibitors
|
US9949976B2
(en)
|
2013-12-31 |
2018-04-24 |
Xuanzhu Pharma Co., Ltd. |
Kinase inhibitor and use thereof
|
CA2935103C
(en)
|
2013-12-31 |
2018-08-28 |
Xuanzhu Pharma Co., Ltd. |
Kinase inhibitor and use thereof
|
US9695165B2
(en)
|
2014-01-15 |
2017-07-04 |
Blueprint Medicines Corporation |
Inhibitors of the fibroblast growth factor receptor
|
US9717735B2
(en)
|
2014-04-17 |
2017-08-01 |
G1 Therapeutics, Inc. |
Tricyclic lactams for use in HSPC-sparing treatments for RB-positive abnormal cellular proliferation
|
US10555931B2
(en)
|
2014-05-28 |
2020-02-11 |
Piramal Enterprises Limited |
Pharmaceutical combination for the treatment of cancer
|
MY187555A
(en)
|
2014-07-24 |
2021-09-29 |
Beta Pharma Inc |
2-h-indazole derivatives as cyclin-dependent kinase (cdk) inhibitors and therapeutic uses thereof
|
CA2954189A1
(en)
*
|
2014-07-26 |
2016-02-04 |
Sunshine Lake Pharma Co., Ltd. |
2-amino-pyrido[2,3-d]pyrimidin-7(8h)-one derivatives as cdk inhibitors and uses thereof
|
WO2016016769A1
(en)
*
|
2014-07-31 |
2016-02-04 |
Sun Pharmaceutical Industries Limited |
A process for the preparation of palbociclib
|
AR101504A1
(es)
*
|
2014-08-11 |
2016-12-21 |
Acerta Pharma Bv |
Combinaciones terapéuticas de un inhibidor de la btk, un inhibidor de la pi3k, un inhibidor de la jak-2, y/o un inhibidor de la cdk4/6
|
EP3180007A1
(en)
*
|
2014-08-14 |
2017-06-21 |
Sun Pharmaceutical Industries Ltd |
Crystalline forms of palbociclib
|
WO2016040858A1
(en)
|
2014-09-12 |
2016-03-17 |
G1 Therapeutics, Inc. |
Combinations and dosing regimes to treat rb-positive tumors
|
WO2016040848A1
(en)
|
2014-09-12 |
2016-03-17 |
G1 Therapeutics, Inc. |
Treatment of rb-negative tumors using topoisomerase inhibitors in combination with cyclin dependent kinase 4/6 inhibitors
|
CN105111201B
(zh)
*
|
2014-10-16 |
2017-01-11 |
上海页岩科技有限公司 |
5-甲基-2-(吡啶-2-基氨基)-8H-吡啶并[2,3-d]嘧啶-7-酮化合物
|
US10851105B2
(en)
|
2014-10-22 |
2020-12-01 |
Incyte Corporation |
Bicyclic heterocycles as FGFR4 inhibitors
|
WO2016066420A1
(en)
*
|
2014-10-29 |
2016-05-06 |
Sandoz Ag |
Crystalline forms of palbociclib monohydrochloride
|
CN105622638B
(zh)
*
|
2014-10-29 |
2018-10-02 |
广州必贝特医药技术有限公司 |
嘧啶或吡啶并吡啶酮类化合物及其制备方法和应用
|
CN105616418A
(zh)
*
|
2014-11-07 |
2016-06-01 |
江苏豪森药业集团有限公司 |
含有细胞周期蛋白抑制剂的药物制剂及其制备方法
|
HUE061672T2
(hu)
|
2014-11-12 |
2023-08-28 |
Seagen Inc |
Glikán-interakcióban lévõ vegyületek és felhasználási módszerek
|
CN104447743B
(zh)
*
|
2014-11-26 |
2016-03-02 |
苏州明锐医药科技有限公司 |
帕博西尼的制备方法
|
CN104496983B
(zh)
*
|
2014-11-26 |
2016-06-08 |
苏州明锐医药科技有限公司 |
一种帕博西尼的制备方法
|
WO2016090257A1
(en)
*
|
2014-12-05 |
2016-06-09 |
Crystal Pharmatech Inc. |
Salts and crystalline forms of 6-acetyl-8-cyclopentyl-5-methyl-2((5-(piperazin-1-yl)pyridin-2-yl)amino)pyrido[2,3-d] pyrimidin-7(8h)-one (palbociclib)
|
WO2016092442A1
(en)
*
|
2014-12-08 |
2016-06-16 |
Sun Pharmaceutical Industries Limited |
Processes for the preparation of crystalline forms of palbociclib acetate
|
CN105732615B
(zh)
*
|
2014-12-31 |
2018-05-01 |
山东轩竹医药科技有限公司 |
Cdk激酶抑制剂
|
EP4205743A1
(en)
|
2014-12-31 |
2023-07-05 |
Shenzhen Pharmacin Co., Ltd. |
Pharmaceutical composition and preparation method therefor
|
CN104610254B
(zh)
*
|
2015-01-26 |
2017-02-01 |
新发药业有限公司 |
一种帕博赛布的低成本制备方法
|
CZ201589A3
(cs)
|
2015-02-11 |
2016-08-24 |
Zentiva, K.S. |
Pevné formy soli Palbociclibu
|
TWI690533B
(zh)
|
2015-02-12 |
2020-04-11 |
南北兄弟藥業投資有限公司 |
Cdk類小分子抑制劑的化合物及其用途
|
MA41551A
(fr)
|
2015-02-20 |
2017-12-26 |
Incyte Corp |
Hétérocycles bicycliques utilisés en tant qu'inhibiteurs de fgfr4
|
EP3617205B1
(en)
|
2015-02-20 |
2021-08-04 |
Incyte Corporation |
Bicyclic heterocycles as fgfr inhibitors
|
US9580423B2
(en)
|
2015-02-20 |
2017-02-28 |
Incyte Corporation |
Bicyclic heterocycles as FGFR4 inhibitors
|
AR104068A1
(es)
|
2015-03-26 |
2017-06-21 |
Hoffmann La Roche |
Combinaciones de un compuesto inhibidor de fosfoinosítido 3-cinasa y un compuesto inhibidor de cdk4/6 para el tratamiento del cáncer
|
WO2016156070A1
(en)
|
2015-04-02 |
2016-10-06 |
Sandoz Ag |
Modified particles of palbociclib
|
EP3078663A1
(en)
|
2015-04-09 |
2016-10-12 |
Sandoz Ag |
Modified particles of palbociclib
|
WO2016169422A1
(zh)
*
|
2015-04-22 |
2016-10-27 |
江苏恒瑞医药股份有限公司 |
一种周期素依赖性蛋白激酶抑制剂的结晶形式及其制备方法
|
TWI696617B
(zh)
|
2015-04-28 |
2020-06-21 |
大陸商上海復尚慧創醫藥研究有限公司 |
特定蛋白質激酶抑制劑
|
CN107614499B
(zh)
*
|
2015-05-29 |
2020-09-18 |
帝人制药株式会社 |
吡啶并[3,4-d]嘧啶衍生物及其药学上可允许的盐
|
KR102369405B1
(ko)
*
|
2015-06-04 |
2022-03-02 |
화이자 인코포레이티드 |
팔보시클립의 고체 투여 형태
|
CN104892604B
(zh)
*
|
2015-06-19 |
2016-08-24 |
北京康立生医药技术开发有限公司 |
一种cdk4抑制剂的合成方法
|
CN106699785A
(zh)
*
|
2015-07-13 |
2017-05-24 |
南开大学 |
作为CDK4/6抑制剂的2-(N-氧化吡啶-2基氨基)-吡啶并[2,3-d]嘧啶-7-酮类化合物
|
EP3331881B1
(en)
|
2015-08-05 |
2019-05-15 |
ratiopharm GmbH |
New crystalline form and acetic acid adducts of palbociclib
|
CN105085517B
(zh)
*
|
2015-08-06 |
2016-11-23 |
天津华洛康生物科技有限公司 |
一种结晶型帕博西尼游离碱水合物及其制备方法
|
CN105130986B
(zh)
*
|
2015-09-30 |
2017-07-18 |
广州科擎新药开发有限公司 |
嘧啶或吡啶并吡啶酮类化合物及其应用
|
HU230962B1
(hu)
|
2015-10-28 |
2019-06-28 |
Egis Gyógyszergyár Zrt. |
Palbociclib sók
|
CN106632311B
(zh)
|
2015-11-02 |
2021-05-18 |
上海科胜药物研发有限公司 |
一种帕博西尼晶型a和晶型b的制备方法
|
AU2016353153B2
(en)
|
2015-11-12 |
2023-11-23 |
Seagen Inc. |
Glycan-interacting compounds and methods of use
|
CN105418603A
(zh)
*
|
2015-11-17 |
2016-03-23 |
重庆莱美药业股份有限公司 |
一种高纯度帕布昔利布及其反应中间体的制备方法
|
CN106810536A
(zh)
|
2015-11-30 |
2017-06-09 |
甘李药业股份有限公司 |
一种蛋白激酶抑制剂及其制备方法和医药用途
|
WO2017101763A1
(en)
|
2015-12-13 |
2017-06-22 |
Hangzhou Innogate Pharma Co., Ltd. |
Heterocycles useful as anti-cancer agents
|
JP6663021B2
(ja)
*
|
2015-12-31 |
2020-03-11 |
シャンハイ ファーマシューティカルズ ホールディング カンパニー,リミティド |
窒素含有縮合複素環化合物、製造方法、中間体、組成物および使用
|
CN105418609B
(zh)
*
|
2015-12-31 |
2017-06-23 |
山东大学 |
4‑(1,2,3‑三氮唑取代苯胺基)‑吡啶骈嘧啶酮衍生物及其制备方法与应用
|
CN106967061A
(zh)
*
|
2016-01-13 |
2017-07-21 |
常州方楠医药技术有限公司 |
帕博西林的盐、晶型及其制备方法
|
WO2017130219A1
(en)
|
2016-01-25 |
2017-08-03 |
Mylan Laboratories Limited |
Amorphous solid dispersion of palbociclib
|
WO2017145054A1
(en)
|
2016-02-24 |
2017-08-31 |
Lupin Limited |
Modified particles of crystalline palbociclib free base and process for the preparation thereof
|
US11077110B2
(en)
|
2016-03-18 |
2021-08-03 |
Tufts Medical Center |
Compositions and methods for treating and preventing metabolic disorders
|
US10449195B2
(en)
|
2016-03-29 |
2019-10-22 |
Shenzhen Pharmacin Co., Ltd. |
Pharmaceutical formulation of palbociclib and a preparation method thereof
|
CN107266421B
(zh)
*
|
2016-04-08 |
2020-12-04 |
正大天晴药业集团股份有限公司 |
取代的苯并咪唑类衍生物
|
CN107286180B
(zh)
*
|
2016-04-11 |
2019-07-02 |
上海勋和医药科技有限公司 |
杂代吡啶并嘧啶酮衍生物作为cdk抑制剂及其应用
|
JP6921115B2
(ja)
*
|
2016-04-22 |
2021-08-18 |
デイナ ファーバー キャンサー インスティチュート,インコーポレイテッド |
サイクリン依存性キナーゼ4/6(cdk4/6)阻害剤のe3リガーゼリガンドとのコンジュゲーションによるcdk4/6の分解および使用法
|
CN106336411B
(zh)
*
|
2016-04-27 |
2018-03-06 |
上海医药集团股份有限公司 |
Cdk4/6抑制剂帕博西尼高纯度原料药的制备工艺及用途
|
CN105949189B
(zh)
*
|
2016-06-05 |
2017-09-22 |
童明琼 |
一种用于治疗乳腺癌的帕博西尼的制备方法
|
EA201990187A1
(ru)
|
2016-07-01 |
2019-07-31 |
Г1 Терапьютикс, Инк. |
Антипролиферационные средства на основе пиримидина
|
WO2018005863A1
(en)
|
2016-07-01 |
2018-01-04 |
G1 Therapeutics, Inc. |
Pyrimidine-based compounds for the treatment of cancer
|
WO2018005533A1
(en)
|
2016-07-01 |
2018-01-04 |
G1 Therapeutics, Inc. |
Antiproliferative pyrimidine-based compounds
|
US10807978B2
(en)
|
2016-07-04 |
2020-10-20 |
Dr. Reddy's Laboratories Limited |
Process for preparation of palbociclib
|
EP3481825A1
(en)
|
2016-07-07 |
2019-05-15 |
Plantex Ltd. |
Solid state forms of palbociclib dimesylate
|
CN109803968A
(zh)
|
2016-08-15 |
2019-05-24 |
辉瑞公司 |
吡啶并嘧啶酮cdk2/4/6抑制剂
|
CA3034875C
(en)
|
2016-08-23 |
2024-05-28 |
Eisai R&D Management Co., Ltd. |
Combination therapies for the treatment of hepatocellular carcinoma
|
WO2018049233A1
(en)
|
2016-09-08 |
2018-03-15 |
Nicolas Stransky |
Inhibitors of the fibroblast growth factor receptor in combination with cyclin-dependent kinase inhibitors
|
US10710999B2
(en)
|
2016-10-07 |
2020-07-14 |
Mylan Laboratories Limited |
Polymorph of an intermediate for palbociclib synthesis
|
EP3528812B1
(en)
|
2016-10-20 |
2020-12-30 |
Pfizer Inc |
Palbociclib for treating pah
|
WO2018073574A1
(en)
|
2016-10-20 |
2018-04-26 |
Cipla Limited |
Polymorphic forms of palbociclib
|
CN106565707B
(zh)
*
|
2016-11-03 |
2019-01-04 |
杭州科巢生物科技有限公司 |
帕博西尼新合成方法
|
EP3538148A1
(en)
|
2016-11-08 |
2019-09-18 |
Dana-Farber Cancer Institute |
Compositions and methods of modulating anti-tumor immunity
|
WO2018091999A1
(en)
|
2016-11-16 |
2018-05-24 |
Pfizer Inc. |
Combination of an egfr t790m inhibitor and a cdk inhibitor for the treatment of non-small cell lung cancer
|
EP3541847A4
(en)
|
2016-11-17 |
2020-07-08 |
Seattle Genetics, Inc. |
COMPOUNDS INTERACTING WITH GLYCANE AND METHODS OF USE
|
DK3546456T3
(da)
|
2016-11-28 |
2022-03-07 |
Teijin Pharma Ltd |
Krystal af pyrido[3, 4-d]pyrimidinderivat eller solvat deraf
|
CN110036012B
(zh)
|
2016-11-28 |
2022-05-10 |
帝人制药株式会社 |
吡啶并[3,4-d]嘧啶衍生物及其药学上可接受的盐
|
US10676474B2
(en)
|
2016-12-16 |
2020-06-09 |
Cstone Pharmaceuticals |
1,6-naphthyridine derivatives as CDK4/6 inhibitor
|
MX2019008158A
(es)
|
2017-01-06 |
2019-12-09 |
G1 Therapeutics Inc |
Terapia de combinacion para el tratamiento del cancer.
|
CN108191857B
(zh)
*
|
2017-01-24 |
2020-10-23 |
晟科药业(江苏)有限公司 |
6-取代的吡啶并[2,3-d]嘧啶类化合物作为蛋白激酶抑制剂
|
US10729692B2
(en)
*
|
2017-02-26 |
2020-08-04 |
Institute For Cancer Research |
Dual inhibition of CDK and HSP90 destabilize HIF1alpha and synergistically induces cancer cell death
|
EP3589319A4
(en)
|
2017-03-03 |
2021-07-14 |
Seagen Inc. |
COMPOUNDS INTERACTING WITH GLYCAN AND METHODS OF USE
|
US11192890B2
(en)
*
|
2017-03-03 |
2021-12-07 |
Auckland Uniservices Limited |
FGFR kinase inhibitors and pharmaceutical uses
|
EP4218820A3
(en)
|
2017-03-16 |
2023-09-20 |
Eisai R&D Management Co., Ltd. |
Combination therapies for the treatment of breast cancer
|
CN108658854A
(zh)
*
|
2017-03-28 |
2018-10-16 |
中国海洋大学 |
一种生物碱化合物及其制备方法和作为海洋防污剂的应用
|
CN108658855A
(zh)
*
|
2017-03-28 |
2018-10-16 |
中国海洋大学 |
一种含氮双环化合物及其制备方法和用途
|
WO2018183921A1
(en)
|
2017-04-01 |
2018-10-04 |
The Broad Institute, Inc. |
Methods and compositions for detecting and modulating an immunotherapy resistance gene signature in cancer
|
AR111960A1
(es)
|
2017-05-26 |
2019-09-04 |
Incyte Corp |
Formas cristalinas de un inhibidor de fgfr y procesos para su preparación
|
TW201904577A
(zh)
|
2017-06-16 |
2019-02-01 |
美商貝達醫藥公司 |
N-(2-(2-二甲胺基)乙氧基)-4-甲氧基-5-((4-(1-甲基-1h-吲哚-3-基)嘧啶-2-基)胺基)苯基)丙烯醯胺及其鹽之醫藥調配物
|
KR102659211B1
(ko)
|
2017-06-29 |
2024-04-18 |
쥐원 쎄라퓨틱스, 인크. |
G1t38의 형체 형태 및 그의 제조 방법
|
EA036060B1
(ru)
*
|
2017-07-17 |
2020-09-21 |
Пфайзер Инк. |
Пиридопиримидиноновые ингибиторы cdk2/4/6
|
US11529353B2
(en)
|
2017-07-28 |
2022-12-20 |
Synthon B.V. |
Pharmaceutical composition comprising Palbociclib
|
CN109384767B
(zh)
*
|
2017-08-08 |
2020-05-05 |
江苏恒瑞医药股份有限公司 |
一种吡啶并嘧啶类衍生物的制备方法及其中间体
|
EP3676404A1
(en)
|
2017-08-31 |
2020-07-08 |
Novartis AG |
Methods of selecting a treatment for cancer patients
|
CN107488175A
(zh)
*
|
2017-09-04 |
2017-12-19 |
上海微巨实业有限公司 |
一种帕博西林关键中间体的制备方法
|
WO2019070755A1
(en)
|
2017-10-02 |
2019-04-11 |
The Broad Institute, Inc. |
METHODS AND COMPOSITIONS FOR DETECTING AND MODULATING A GENETIC SIGNATURE OF IMMUNOTHERAPY RESISTANCE IN CANCER
|
WO2019126731A1
(en)
|
2017-12-22 |
2019-06-27 |
Petra Pharma Corporation |
Aminopyridine derivatives as phosphatidylinositol phosphate kinase inhibitors
|
CN108586452A
(zh)
*
|
2018-01-12 |
2018-09-28 |
重庆市碚圣医药科技股份有限公司 |
一种帕博西尼中间体的合成方法
|
US11352341B2
(en)
|
2018-01-29 |
2022-06-07 |
Beta Pharma, Inc. |
2H-indazole derivatives as CDK4 and CDK6 inhibitors and therapeutic uses thereof
|
CN108218861B
(zh)
*
|
2018-02-05 |
2019-07-23 |
黑龙江中医药大学 |
一种预防和治疗糖尿病的药物及其制备方法
|
WO2019157020A1
(en)
|
2018-02-06 |
2019-08-15 |
The Board Of Trustees Of The University Of Illinois |
Substituted benzothiophene analogs as selective estrogen receptor degraders
|
JP7474709B2
(ja)
|
2018-02-27 |
2024-04-25 |
インサイト・コーポレイション |
A2a/a2b阻害剤としてのイミダゾピリミジン及びトリアゾロピリミジン
|
CA3092003A1
(en)
|
2018-02-27 |
2019-09-06 |
Pfizer Inc. |
Combination of a cyclin dependent kinase inhibitor and a bet-bromodomain inhibitor
|
SG11202010636VA
(en)
|
2018-05-04 |
2020-11-27 |
Incyte Corp |
Solid forms of an fgfr inhibitor and processes for preparing the same
|
BR112020022373A2
(pt)
|
2018-05-04 |
2021-02-02 |
Incyte Corporation |
sais de um inibidor de fgfr
|
AU2019269159A1
(en)
|
2018-05-14 |
2020-11-19 |
Pfizer Inc. |
Oral solution formulation
|
CA3100731A1
(en)
|
2018-05-18 |
2019-11-21 |
Incyte Corporation |
Fused pyrimidine derivatives as a2a / a2b inhibitors
|
EP4289844A3
(en)
|
2018-05-24 |
2024-04-10 |
Synthon B.V. |
A process for making palbociclib
|
CN113166153A
(zh)
|
2018-07-05 |
2021-07-23 |
因赛特公司 |
作为a2a/a2b抑制剂的稠合吡嗪衍生物
|
CA3106273A1
(en)
|
2018-07-23 |
2020-01-30 |
F. Hoffmann-La Roche Ag |
Methods of treating cancer with pi3k inhibitor, gdc-0077
|
EP3840756A4
(en)
|
2018-08-24 |
2022-04-27 |
G1 Therapeutics, Inc. |
IMPROVED SYNTHESIS OF 1,4-DIAZASPIRO[5.5]UNDECAN-3-ONE
|
JP6952747B2
(ja)
|
2018-09-18 |
2021-10-20 |
ファイザー・インク |
がん処置のためのTGFβ阻害剤およびCDK阻害剤の組合せ
|
JP2022504388A
(ja)
|
2018-10-08 |
2022-01-13 |
エフ・ホフマン-ラ・ロシュ・アクチェンゲゼルシャフト |
Pi3kアルファ阻害剤およびメトホルミンを用いたがんの処置方法
|
US11066404B2
(en)
|
2018-10-11 |
2021-07-20 |
Incyte Corporation |
Dihydropyrido[2,3-d]pyrimidinone compounds as CDK2 inhibitors
|
WO2020114519A1
(zh)
*
|
2018-12-07 |
2020-06-11 |
杭州英创医药科技有限公司 |
作为cdk-hdac双通路抑制剂的杂环化合物
|
BR112021011894A2
(pt)
|
2018-12-21 |
2021-09-08 |
Daiichi Sankyo Company, Limited |
Composição farmacêutica
|
CA3124574A1
(en)
*
|
2018-12-28 |
2020-07-02 |
Spv Therapeutics Inc. |
Cyclin-dependent kinase inhibitors
|
TWI829857B
(zh)
|
2019-01-29 |
2024-01-21 |
美商英塞特公司 |
作為a2a / a2b抑制劑之吡唑并吡啶及三唑并吡啶
|
WO2020157709A1
(en)
|
2019-02-01 |
2020-08-06 |
Pfizer Inc. |
Combination of a cdk inhibitor and a pim inhibitor
|
WO2020168178A1
(en)
*
|
2019-02-15 |
2020-08-20 |
Incyte Corporation |
Cyclin-dependent kinase 2 biomarkers and uses thereof
|
WO2020168197A1
(en)
|
2019-02-15 |
2020-08-20 |
Incyte Corporation |
Pyrrolo[2,3-d]pyrimidinone compounds as cdk2 inhibitors
|
TW202100520A
(zh)
|
2019-03-05 |
2021-01-01 |
美商英塞特公司 |
作為cdk2 抑制劑之吡唑基嘧啶基胺化合物
|
WO2020185532A1
(en)
|
2019-03-08 |
2020-09-17 |
Incyte Corporation |
Methods of treating cancer with an fgfr inhibitor
|
WO2020186101A1
(en)
|
2019-03-12 |
2020-09-17 |
The Broad Institute, Inc. |
Detection means, compositions and methods for modulating synovial sarcoma cells
|
WO2020205560A1
(en)
|
2019-03-29 |
2020-10-08 |
Incyte Corporation |
Sulfonylamide compounds as cdk2 inhibitors
|
WO2020223469A1
(en)
|
2019-05-01 |
2020-11-05 |
Incyte Corporation |
N-(1-(methylsulfonyl)piperidin-4-yl)-4,5-di hydro-1h-imidazo[4,5-h]quinazolin-8-amine derivatives and related compounds as cyclin-dependent kinase 2 (cdk2) inhibitors for treating cancer
|
US11447494B2
(en)
|
2019-05-01 |
2022-09-20 |
Incyte Corporation |
Tricyclic amine compounds as CDK2 inhibitors
|
EP3976043A1
(en)
|
2019-05-24 |
2022-04-06 |
Pfizer Inc. |
Combination therapies using cdk inhibitors
|
AU2020281535A1
(en)
|
2019-05-24 |
2022-01-27 |
Merck Patent Gmbh |
Combination therapies using CDK inhibitors
|
CN112010844B
(zh)
*
|
2019-05-31 |
2023-07-25 |
中国药科大学 |
N-(嘧啶-2-基)香豆素-7-胺衍生物作为蛋白激酶抑制剂的制法和应用
|
TW202112767A
(zh)
|
2019-06-17 |
2021-04-01 |
美商佩特拉製藥公司 |
作為磷脂酸肌醇磷酸激酶抑制劑之胺基吡啶衍生物
|
CN112094272A
(zh)
|
2019-06-18 |
2020-12-18 |
北京睿熙生物科技有限公司 |
Cdk激酶抑制剂
|
TW202114685A
(zh)
*
|
2019-06-20 |
2021-04-16 |
大陸商江蘇恒瑞醫藥股份有限公司 |
藥物組合物以及其製備方法
|
CN110143948B
(zh)
*
|
2019-06-21 |
2021-05-14 |
上海博悦生物科技有限公司 |
Cdk4/6抑制剂、其药物组合物、制备方法及应用
|
WO2021007269A1
(en)
|
2019-07-09 |
2021-01-14 |
Incyte Corporation |
Bicyclic heterocycles as fgfr inhibitors
|
US20210030869A1
(en)
|
2019-08-01 |
2021-02-04 |
Incyte Corporation |
Dosing regimen for an ido inhibitor
|
US11427567B2
(en)
|
2019-08-14 |
2022-08-30 |
Incyte Corporation |
Imidazolyl pyrimidinylamine compounds as CDK2 inhibitors
|
CN115298177A
(zh)
|
2019-10-11 |
2022-11-04 |
因赛特公司 |
作为cdk2抑制剂的双环胺
|
BR112022007163A2
(pt)
|
2019-10-14 |
2022-08-23 |
Incyte Corp |
Heterociclos bicíclicos como inibidores de fgfr
|
US11566028B2
(en)
|
2019-10-16 |
2023-01-31 |
Incyte Corporation |
Bicyclic heterocycles as FGFR inhibitors
|
CN112759589B
(zh)
*
|
2019-11-01 |
2022-04-08 |
暨南大学 |
嘧啶并吡啶酮类化合物及其应用
|
CN114901659A
(zh)
|
2019-11-26 |
2022-08-12 |
施万生物制药研发Ip有限责任公司 |
作为jak抑制剂的稠合嘧啶吡啶酮化合物
|
JP2023504436A
(ja)
|
2019-12-03 |
2023-02-03 |
ジェネンテック, インコーポレイテッド |
乳がんの治療のための併用療法
|
PE20221504A1
(es)
|
2019-12-04 |
2022-09-30 |
Incyte Corp |
Derivados de un inhibidor de fgfr
|
EP4069696A1
(en)
|
2019-12-04 |
2022-10-12 |
Incyte Corporation |
Tricyclic heterocycles as fgfr inhibitors
|
CR20220342A
(es)
*
|
2019-12-16 |
2023-01-23 |
Lunella Biotech Inc |
Agentes terapéuticos selectivos contra el cáncer inhibidores cdk4/6
|
WO2021146424A1
(en)
|
2020-01-15 |
2021-07-22 |
Incyte Corporation |
Bicyclic heterocycles as fgfr inhibitors
|
TW202146017A
(zh)
|
2020-03-05 |
2021-12-16 |
美商輝瑞股份有限公司 |
間變性淋巴瘤激酶抑制劑及周期蛋白依賴型激酶抑制劑之組合
|
AU2021230385A1
(en)
|
2020-03-06 |
2022-09-22 |
Incyte Corporation |
Combination therapy comprising AXL/MER and PD-1/PD-L1 inhibitors
|
WO2021183994A1
(en)
*
|
2020-03-13 |
2021-09-16 |
Prosenestar Llc |
Pyrido[2,3-d]pyrimidin-7(8h)-ones as cdk inhibitors
|
JP2021167301A
(ja)
|
2020-04-08 |
2021-10-21 |
ファイザー・インク |
Cdk2阻害剤に対する腫瘍適応を抑制するためのcdk4/6およびcdk2阻害剤による同時処置
|
WO2021211864A1
(en)
|
2020-04-16 |
2021-10-21 |
Incyte Corporation |
Fused tricyclic kras inhibitors
|
WO2021231526A1
(en)
|
2020-05-13 |
2021-11-18 |
Incyte Corporation |
Fused pyrimidine compounds as kras inhibitors
|
MX2022014573A
(es)
|
2020-05-19 |
2022-12-15 |
G1 Therapeutics Inc |
Compuestos inhibidores de cinasa dependiente de ciclina para el tratamiento de trastornos medicos.
|
US20230132667A1
(en)
*
|
2020-05-28 |
2023-05-04 |
University Of Washington |
Drug-like molecules and methods for the therapeutic targeting of viral rna structures
|
US10988479B1
(en)
|
2020-06-15 |
2021-04-27 |
G1 Therapeutics, Inc. |
Morphic forms of trilaciclib and methods of manufacture thereof
|
CN113880809B
(zh)
|
2020-07-03 |
2022-10-18 |
盛世泰科生物医药技术(苏州)有限公司 |
一种嘧啶类衍生物及其制备方法和应用
|
AU2021308406A1
(en)
|
2020-07-15 |
2023-02-23 |
Ctxt Pty Ltd |
KAT6 inhibitor methods and combinations for cancer treatment
|
EP4181919A1
(en)
|
2020-07-20 |
2023-05-24 |
Pfizer Inc. |
Combination therapy
|
WO2022047093A1
(en)
|
2020-08-28 |
2022-03-03 |
Incyte Corporation |
Vinyl imidazole compounds as inhibitors of kras
|
WO2022063119A1
(zh)
*
|
2020-09-24 |
2022-03-31 |
南京济群医药科技股份有限公司 |
一种羟乙磺酸哌柏西利的组合物及药物
|
CN114306245A
(zh)
|
2020-09-29 |
2022-04-12 |
深圳市药欣生物科技有限公司 |
无定形固体分散体的药物组合物及其制备方法
|
WO2022072783A1
(en)
|
2020-10-02 |
2022-04-07 |
Incyte Corporation |
Bicyclic dione compounds as inhibitors of kras
|
WO2022091001A1
(en)
|
2020-10-29 |
2022-05-05 |
Pfizer Ireland Pharmaceuticals |
Process for preparation of palbociclib
|
WO2022123419A1
(en)
|
2020-12-08 |
2022-06-16 |
Pfizer Inc. |
Treatment of luminal subtypes of hr-positive, her2-negative early breast cancer with palbociclib
|
CN112569361B
(zh)
*
|
2020-12-30 |
2023-01-10 |
扬子江药业集团上海海尼药业有限公司 |
一种哌柏西利干混悬组合物及其制备方法
|
WO2022155941A1
(en)
|
2021-01-25 |
2022-07-28 |
Qilu Regor Therapeutics Inc. |
Cdk2 inhibitors
|
WO2022162122A1
(en)
|
2021-01-29 |
2022-08-04 |
Biotx.Ai Gmbh |
Genetically verified netosis inhibitor for use in the treatment of a sars-cov2 infection
|
WO2022206888A1
(en)
|
2021-03-31 |
2022-10-06 |
Qilu Regor Therapeutics Inc. |
Cdk2 inhibitors and use thereof
|
JP2024513575A
(ja)
|
2021-04-12 |
2024-03-26 |
インサイト・コーポレイション |
Fgfr阻害剤及びネクチン-4標的化剤を含む併用療法
|
EP4352060A1
(en)
|
2021-06-09 |
2024-04-17 |
Incyte Corporation |
Tricyclic heterocycles as fgfr inhibitors
|
JP2024522189A
(ja)
|
2021-06-09 |
2024-06-11 |
インサイト・コーポレイション |
Fgfr阻害剤としての三環式ヘテロ環
|
US11981671B2
(en)
|
2021-06-21 |
2024-05-14 |
Incyte Corporation |
Bicyclic pyrazolyl amines as CDK2 inhibitors
|
KR20240032915A
(ko)
|
2021-07-07 |
2024-03-12 |
인사이트 코포레이션 |
Kras의 저해제로서의 삼환식 화합물
|
JP2024529347A
(ja)
|
2021-07-14 |
2024-08-06 |
インサイト・コーポレイション |
Krasの阻害剤としての三環式化合物
|
US20230022525A1
(en)
|
2021-07-26 |
2023-01-26 |
Celcuity Inc. |
Methods for the treatment of cancer using 1-(4-{[4-(dimethylamino)piperidin-1-yl]carbonyl}phenyl)-3-[4-(4,6-dimorpholin-4-yl-1,3,5-triazin-2-yl)phenyl]urea
|
EP4396187A1
(en)
|
2021-08-31 |
2024-07-10 |
Incyte Corporation |
Naphthyridine compounds as inhibitors of kras
|
CN113683612B
(zh)
*
|
2021-09-07 |
2022-06-17 |
山东铂源药业股份有限公司 |
一种帕布昔利布的制备方法
|
WO2023040914A1
(zh)
*
|
2021-09-14 |
2023-03-23 |
甘李药业股份有限公司 |
一种cdk4/6抑制剂的医药用途
|
WO2023049697A1
(en)
|
2021-09-21 |
2023-03-30 |
Incyte Corporation |
Hetero-tricyclic compounds as inhibitors of kras
|
EP4408536A1
(en)
|
2021-10-01 |
2024-08-07 |
Incyte Corporation |
Pyrazoloquinoline kras inhibitors
|
US11939328B2
(en)
|
2021-10-14 |
2024-03-26 |
Incyte Corporation |
Quinoline compounds as inhibitors of KRAS
|
AU2022389961A1
(en)
|
2021-11-22 |
2024-06-06 |
Incyte Corporation |
Combination therapy comprising an fgfr inhibitor and a kras inhibitor
|
WO2023102184A1
(en)
|
2021-12-03 |
2023-06-08 |
Incyte Corporation |
Bicyclic amine compounds as cdk12 inhibitors
|
US20230183251A1
(en)
|
2021-12-10 |
2023-06-15 |
Incyte Corporation |
Bicyclic amines as cdk12 inhibitors
|
US11976073B2
(en)
|
2021-12-10 |
2024-05-07 |
Incyte Corporation |
Bicyclic amines as CDK2 inhibitors
|
KR20240118134A
(ko)
|
2021-12-10 |
2024-08-02 |
일라이 릴리 앤드 캄파니 |
Cdk4 및 6 억제제로 이전에 치료된 환자에서의 호르몬 수용체-양성, 인간 표피 성장 인자 수용체 2-음성 진행성 또는 전이성 유방암의 치료를 위한 풀베스트란트와 조합된 cdk4 및 6 억제제
|
WO2023111810A1
(en)
|
2021-12-14 |
2023-06-22 |
Pfizer Inc. |
Combination therapies and uses for treating cancer
|
WO2023114264A1
(en)
|
2021-12-15 |
2023-06-22 |
Eli Lilly And Company |
Combination for treatment of high-risk metastatic hormone-sensitive prostate cancer
|
US20230192722A1
(en)
|
2021-12-22 |
2023-06-22 |
Incyte Corporation |
Salts and solid forms of an fgfr inhibitor and processes of preparing thereof
|
WO2023168686A1
(en)
|
2022-03-11 |
2023-09-14 |
Qilu Regor Therapeutics Inc. |
Substituted cyclopentanes as cdk2 inhibitors
|
WO2023116884A1
(en)
|
2021-12-24 |
2023-06-29 |
Qilu Regor Therapeutics Inc. |
Cdk2 inhibitors and use thereof
|
CN114456180B
(zh)
*
|
2022-02-18 |
2023-07-25 |
贵州大学 |
用于治疗和/或预防恶性肿瘤的化合物及药物制剂和应用
|
WO2023172921A1
(en)
|
2022-03-07 |
2023-09-14 |
Incyte Corporation |
Solid forms, salts, and processes of preparation of a cdk2 inhibitor
|
HUP2200147A1
(hu)
*
|
2022-05-10 |
2023-11-28 |
Egyt Gyogyszervegyeszeti Gyar |
Palbociclibet és letrozolt tartalmazó gyógyszerkészítmény
|
TW202413359A
(zh)
|
2022-06-22 |
2024-04-01 |
美商英塞特公司 |
雙環胺cdk12抑制劑
|
EP4302755A1
(en)
|
2022-07-07 |
2024-01-10 |
Lotus Pharmaceutical Co., Ltd. |
Palbociclib formulation containing an amino acid
|
EP4302832A1
(en)
|
2022-07-07 |
2024-01-10 |
Lotus Pharmaceutical Co., Ltd. |
Palbociclib formulation containing glucono delta lactone
|
US20240101557A1
(en)
|
2022-07-11 |
2024-03-28 |
Incyte Corporation |
Fused tricyclic compounds as inhibitors of kras g12v mutants
|
CN117430597A
(zh)
*
|
2022-07-14 |
2024-01-23 |
浙江同源康医药股份有限公司 |
用作cdk4激酶抑制剂的化合物及其应用
|
WO2024023703A1
(en)
|
2022-07-29 |
2024-02-01 |
Pfizer Inc. |
Dosing regimens comprising a kat6 inhibitor for the treatment of cancer
|
WO2024049926A1
(en)
|
2022-08-31 |
2024-03-07 |
Arvinas Operations, Inc. |
Dosage regimens of estrogen receptor degraders
|
JP2024067010A
(ja)
|
2022-11-02 |
2024-05-16 |
ペトラ・ファーマ・コーポレイション |
疾患の治療用のホスホイノシチド3-キナーゼ(pi3k)のアロステリッククロメノン阻害剤
|
WO2024100236A1
(en)
|
2022-11-11 |
2024-05-16 |
Astrazeneca Ab |
Combination therapies for the treatment of cancer
|
WO2024125581A2
(zh)
*
|
2022-12-16 |
2024-06-20 |
上海岸阔医药科技有限公司 |
化合物及其用途
|
WO2024133726A1
(en)
|
2022-12-22 |
2024-06-27 |
Synthon B.V. |
Pharmaceutical composition comprising palbociclib
|
WO2024132652A1
(en)
|
2022-12-22 |
2024-06-27 |
Synthon B.V. |
Pharmaceutical composition comprising palbociclib
|